Brief communications: changes in inflammatory biomarkers and lipid profiles after switching to long-acting cabotegravir plus rilpivirine

Journal article

We assessed whether the impact of cabotegravir plus rilpivirine on inflammation reduction differs from that of oral antiretrovirals, using real-world data. Inflammatory biomarkers and lipid profiles were followed from baseline to 8 months after switching. Seventy-eight participants were analyzed. The CD4/CD8 ratio and C-reactive protein did not change. There were transient decreases in CD8 and CD4 counts in the group that switched from the dolutegravir-based regimen, but not in the tenofovir alafenamide-based regimen group. High-density lipoprotein (HDL) cholesterol increased, resulting in a decrease in the total-cholesterol to HDL cholesterol ratio, whereas there was no significant change in low-density lipoprotein cholesterol.

Authors: Adachi, E; Saito, M; Otani, A; Koga, M; Yotsuyanagi, H

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: BioMed Central
• Journal: AIDS Research and Therapy
• Volume: 21
• Issue: 1
• Pages: 1-1
• Article number: 1
• Publication date: 2024-01-03
• DOI: 10.1186/s12981-023-00590-4
• EISSN: 1742-6405
• ISSN: 1742-6405
• Language: English
• Keywords: Antiretroviral therapy; Dolutegravir; Rilpivirine; Immunology; Pharmacology; Tenofovir alafenamide; Regimen; Viral load; Medicine; Internal medicine; Human immunodeficiency virus (HIV); Cholesterol